Special Issue

Microparticle-Based Vaccines

Message from the Guest Editor

This special issue will highlight and bring out the state of the art in the development of microparticle-based vaccines, a transcendent approach for vaccine design not only against infectious diseases, but also for stimulating immune responses against cancer. Particulate carriers offer several attributes for use as vaccine delivery systems. First, microparticles can mimic the size of the pathogens that the immune system has evolved to combat and, consequently, they are efficiently better recognized and internalized by antigen presenting cells, facilitating the uptake of the antigens (or genetic material) carried. In addition, these particulate systems can present multiple copies of the antigens, not only on their surface but also forming part of the internal particle structure, protecting the antigens from degradation and increasing the antigen persistence. As a guest editor of this Special Issue, I invite you to submit research and review articles related to this special edition, which will help researchers in the vaccinology field to develop and improve new vaccine strategies based in these particulate platforms.

Guest Editor

Dr. Alejandro Marin-Lopez

Department of Internal Medicine, Section of Infectious Diseases, School of Medicine, Yale University, New Haven, CT, USA

Deadline for manuscript submissions

closed (15 August 2022)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/90248

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI